万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生2>>血液学

JOURNAL OF CLINICAL APHERESIS《临床单采术杂志》 (官网投稿)

简介
  • 期刊简称J CLIN APHERESIS
  • 参考译名《临床单采术杂志》
  • 核心类别 SCIE(2024版), 目次收录(维普),外文期刊,
  • IF影响因子
  • 自引率20.00%
  • 主要研究方向医学-HEMATOLOGY 血液学

主要研究方向:

等待设置主要研究方向
医学-HEMATOLOGY 血液学

JOURNAL OF CLINICAL APHERESIS《临床单采术杂志》(双月刊). The Journal of Clinical Apheresis publishes articles dealing with all aspects of hemapheresis.&...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿

2期刊网址:

https://onlinelibrary.wiley.com/journal/10981101

3投稿网址:http://mc.manuscriptcentral.com/jca

4、官网邮箱:jcaeditorial@wiley.com(投稿咨询)

winters.jeffrey@mayo.edu(主编)

5、官网电话:(507) 538-1707(主编)

6、期刊刊期:双月刊,一年出版6期。

2021年8月16日星期

                                 

 

投稿须知【官网信息】

 

Journal of Clinical Apheresis

Author Guidelines

Authors and reviewers should adhere to the Apheresis Procedure Reporting Guide when preparing and reviewing papers for JCA.

The Journal of Clinical Apheresis now offers free format submission for a simplified and streamlined submission process.

Before you submit, you will need:

Your manuscript: this can be a single file including text, figures, and tables, or separate files – whichever you prefer. All required sections should be contained in your manuscript, including abstract, introduction, methods, results, and conclusions. Figures and tables should have legends. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers. If your manuscript is difficult to read, the editorial office may send it back to you for revision.

The title page of the manuscript, including statements relating to our ethics and integrity policies:

data availability statement

funding statement

conflict of interest disclosure

ethics approval statement

patient consent statement

permission to reproduce material from other sources

clinical trial registration

(Why is this important? We need to uphold rigorous ethical standards for the research we consider for publication.)

Your co-author details, including affiliation and email address. (Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.)

An ORCID ID, freely available at https://orcid.org. (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)

To submit, login at https://mc.manuscriptcentral.com/jca and create a new submission. Follow the submission steps as required and submit the manuscript.

If you are invited to revise your manuscript after peer review, the journal will also request the revised manuscript to be formatted according to journal requirements as described below.

ARTICLE TYPES & MANUSCRIPT PREPARATION

Research Articles

Articles welcomed for review include those reporting basic research and clinical applications of therapeutic plasma exchange, therapeutic cytapheresis, therapeutic absorption, blood component collection and transfusion, donor recruitment and safety, administration of hemapheresis centers, and innovative applications of hemapheresis technology.

Articles should be organized in the following order:

Title Page. This should contain the complete title of the manuscript, the names, titles, and affiliations of all authors, the institution at which the work was performed, the name, address, telephone number, and email address for all correspondence, and a short form of the title, not more than 40 characters, to be used as a running head.

Abstract. This should be a factual condensation of the entire work, including a statement of its purpose. a clear description of the findings, including numbers, and a concise presentation of the conclusions.

……

更多详情:

https://onlinelibrary.wiley.com/page/journal/10981101/homepage/forauthors.html


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭